Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130246 · ClinicalTrials.gov registry record · Phase 3
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
A Phase 3 study, sponsored by Anthera Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5,189
- Enrollment target
NCT01130246 is a Phase 3 study that was terminated before completion, run by Anthera Pharmaceuticals. The registered enrollment target is 5,189 participants.
The verdict
NCT01130246, a Phase 3 study, was terminated before completion, sponsored by Anthera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5,189 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
Interventions
- DRUG Placebo
- DRUG A-002, varespladib methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,189 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130246
The ClinicalTrials.gov registry entry for NCT01130246 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5,189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01130246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130246 about?
NCT01130246 is a clinical study titled "VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome". The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
What is the current status of trial NCT01130246?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5,189 participants. The study started on 2010-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01130246?
The interventions under investigation include: Placebo (DRUG), A-002, varespladib methyl (DRUG).
Who is sponsoring clinical trial NCT01130246?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.